91407-48-6

Basic information

• Product Name: 4,5-DIMETHOXY-2-FLUOROBENZYL CHLORIDE
• Synonyms: 4,5-DIMETHOXY-2-FLUOROBENZYL CHLORIDE;2-FLUORO-4 5-DIMETHOXYBENZL CHLORIDE;2-Fluoro-4,5-dimethoxybenzyl chloride
• CAS NO: 91407-48-6
• Molecular Formula: C₉H₁₀ClFO₂
• Molecular Weight: 204.63
• Mol File: 91407-48-6.mol
• Article Data: 3

Chemical Properties

• Melting Point: 50-54 °C(lit.)
• Flash Point: >230 °F
• Appearance: /
• CAS DataBase Reference: 4,5-DIMETHOXY-2-FLUOROBENZYL CHLORIDE(CAS DataBase Reference)
• NIST Chemistry Reference: 4,5-DIMETHOXY-2-FLUOROBENZYL CHLORIDE(91407-48-6)
• EPA Substance Registry System: 4,5-DIMETHOXY-2-FLUOROBENZYL CHLORIDE(91407-48-6)

Safety Data

• Hazard Codes: C
• Statements: 34
• Safety Statements: 26-36/37/39-45
• RIDADR: UN 1759 8/PG 2
• WGK Germany: 3
• Hazardous Substances Data: 91407-48-6(Hazardous Substances Data)

Usage

Description

4,5-DIMETHOXY-2-FLUOROBENZYL CHLORIDE, also known as (2-Fluoro-4,5-dimethoxybenzyl)chloride, is an organic chemical compound that serves as an intermediate in the synthesis of various pharmaceutical compounds. It is characterized by the presence of a fluorine atom, two methoxy groups, and a benzyl chloride functional group, which contribute to its unique chemical properties and reactivity.

Uses

Used in Pharmaceutical Industry:
4,5-DIMETHOXY-2-FLUOROBENZYL CHLORIDE is used as a synthetic intermediate for the production of 6-Fluoro L-DOPA Hydrobromide Salt (F591546), a fluorinated DOPA analog. This analog is of interest in pharmaceutical research and development due to its potential applications in the treatment of various medical conditions, such as Parkinson's disease and other movement disorders.
As a synthetic intermediate, 4,5-DIMETHOXY-2-FLUOROBENZYL CHLORIDE plays a crucial role in the development of new and innovative pharmaceutical compounds, contributing to advancements in medicine and healthcare. Its unique structure and reactivity make it a valuable component in the synthesis of various bioactive molecules, further expanding its potential applications in the pharmaceutical industry.

Upstream product

• 50-00-0 formaldehyd 
• 398-62-9 4-fluoroveratrole 
• 71924-62-4 2-fluoro-4,5-dimethoxybenzaldehyde 
• 6315-89-5 3,4-dimethoxyaniline 

Downstream Products

• 91407-49-7 2-(2-fluoro-4,5-dimethoxyphenyl)acetonitrile 
• 476359-34-9 (2R)-N-[(2S)-2-((diphenylmethylidene)amino)-2-(2'-fluoro-4',5'-dimethoxybenzyl)-ethan-1-oyl]bornane-10,2-sultam 
• 75290-51-6 3,4-dihydroxy-6-fluoro-L-phenylalanine 
• 476359-42-9 6-fluoro-L-3,4-dimethoxyphenylalanine 
• 476359-38-3 (2R)-N-[(2S)-2-amino-2-(2'-fluoro-4',5'-dimethoxybenzyl)-ethan-1-oyl]bornane-10,2-sultam 
• 125228-10-6 2-(2-fluoro-4,5-dihydroxyphenyl)acetonitrile 
• 125227-99-8 4,5-bis(benzyloxy)-2-fluorobenzyl cyanide 
• 125228-08-2 2-<3,4-bis(benzyloxy)-6-fluorobenzyl>imidazoline 
• 1342888-01-0 N-(2-fluoro-4,5-dimethoxybenzyl)-N-(4-(methylthio)benzyl)-1H-benzo[d]imidazol-5-amine 
• 1416250-83-3 tert-butyl 4-[1-(2-fluoro-4,5-dimethoxybenzyl)-2,4-dioxo-6-phenyl-1,4-dihydrothieno[3,2-d]pyrimidin-3(2H)-yl]piperidine-1-carboxylate 
• 1439376-31-4 2-(4,5-diethoxy-2-fluorophenyl)acetonitrile 

Relevant articles and documents

Synthesis and α2-adrenoceptor effects of substituted catecholimidazoline and catecholimidazole analogues in human platelets

It is known that the steric requirements for the interactions of catecholamines and catecholimidazolines with α1- and α2-adrenoceptors are different. New analogues of desoxycatecholimidazoline (1), desoxycatecholimidazole (3), benzylic hydroxyl substituted imidazole (4), and the aromatic fluorine substitution analogues of 1 at the 2 (5), 5 (6), and 6 (7) positions, and a set of asymmetric 4-substituted catecholimidazolines, S-8 and R-8, were prepared and tested for interaction with α2-adrenoceptors in human platelets. With the exception of 3, all compounds were selective for α-adrenoceptor-mediated responses in human platelets. Introduction of a double bond in imidazoline 1 to give an imidazole 3 or the introduction of a benzylic hydroxyl group to 3, as in 4, reduced the inhibition of platelet aggregation with a rank order potency of 1 > 3 > 4. Fluorine atom substitution at the 2-, 5-, or 6-positions only slightly modified the inhibitory activity of 1. Each analogue (1, 3-7) produced α2-mediated inhibition of platelet adenylate cyclase and can be classified as a partial agonist. The inhibition potency of S-8 and R-8 against epinephrine-induced aggregatory responses were greatly different, and only R-8 and 4 were α2-agonists on human platelet function. Our studies provide further evidence for the differential interaction of catecholamines and catecholimidazolines in α1- and α2-adrenoceptor systems.

SYNTHESIS OF 2,3-DIMETHOXY-5-FLUORO- AND 4,5-DIMETHOXY-2-FLUORO-SUBSTITUTED PHENYLACETIC AND PHENYLACETOHYDROXAMIC ACIDS

Many-stage methods were developed for the synthesis of 2,3-dimethoxy-5-fluorophenylacetic acid from 3-methyl-4,5-dimethoxyaniline and 4,5-dimethoxy-2-fluorophenylacetic acid from 3,4-dimethoxyaniline.Methods were also developed for their conversion into t